Updates in Therapeutic Approaches to PBC Following Elafibranor Approval

News
Video

In this video segment, Palak and Trivedi discuss the approval of elafibranor and other therapies that could receive approval for management of primary biliary cholangitis in the near future.

In this segment of our HCPLive Special Report on Updates and Unmet Needs in PBC, Palak Trivedi, MD, PhD, and James Boyer, MD, focus their discussion on recent therapeutic advancements in primary biliary cholangitis (PBC), particularly the approval of new treatments like elafibranor and the anticipated approval of seladelpar. When prompted, Boyer provides a historical context, noting that the standard of care was previously ursodeoxycholic acid, with a significant portion of patients not responding adequately. He outlines the progression to obeticholic acid, its limitations, and the need for new therapies.

The conversation then highlights the efficacy of elafibranor and seladelpar, both of which have shown promising results in clinical trials. Boyer explains the importance of achieving significant reductions in alkaline phosphatase levels, a key prognostic marker, and the challenges of side effects like pruritus with existing therapies. The discussion underscores the potential of these new treatments to improve patient outcomes and quality of life.

Check out the other segments in this series:

Subject Matter Experts:

  • James Boyer, MD, Ensign Professor of Medicine at Yale School of Medicine and the Founder and Emeritus Director of the Yale Liver Center.
  • Palak Trivedi, MD, PhD, Associate Professor and Honorary Consultant Hepatologist and Clinical Research Director for Industry Engagement at the University of Birmingham. Also serves as an investigator on the open-label ASSURE trial of seladelpar in patients with PBC.
Related Videos
4 KOLs are featured in this series
4 KOLs are featured in this series
M. Safwan Badr, MD: Novel Treatments for Central Sleep Apnea in Last 10 Years
Video 4 - Featuring 3 KOLs in, "Implementing Treat to Target in the Long-term in Inflammatory Bowel Disease "
Video 3 - Featuring 3 KOLs in, "How important is transmural healing as a treatment target in UC and CD?   Where does intestinal ultrasound fit in CD management?  "
How Elite Athletes Can Optimize Sleep for Peak Performance, with Jesse D. Cook, PhD
Boadie Dunlop, MD, Weighs in on FDA Advisory Vote on Lykos’ MDMA
HCPLive Five at ADA 2024 | Image Credit: HCPLive
© 2024 MJH Life Sciences

All rights reserved.